Arbutus Biopharma Corp (ABUS) Expected to Announce Earnings of -$0.39 Per Share

Wall Street analysts expect Arbutus Biopharma Corp (NASDAQ:ABUS) to post earnings of ($0.39) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Arbutus Biopharma’s earnings. Arbutus Biopharma posted earnings of ($0.90) per share during the same quarter last year, which suggests a positive year over year growth rate of 56.7%. The firm is scheduled to announce its next earnings results on Wednesday, March 13th.

According to Zacks, analysts expect that Arbutus Biopharma will report full-year earnings of ($1.27) per share for the current fiscal year, with EPS estimates ranging from ($1.30) to ($1.23). For the next fiscal year, analysts expect that the company will post earnings of ($1.69) per share, with EPS estimates ranging from ($1.80) to ($1.57). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Arbutus Biopharma.

Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.52) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.13). The firm had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $0.23 million. Arbutus Biopharma had a negative return on equity of 91.36% and a negative net margin of 1,116.69%.

A number of brokerages have commented on ABUS. Wedbush upped their price objective on shares of Arbutus Biopharma from $6.00 to $7.00 and gave the stock a “hold” rating in a research report on Monday, August 13th. Chardan Capital cut their price objective on shares of Arbutus Biopharma from $12.00 to $6.50 and set a “buy” rating for the company in a research report on Friday, October 12th. ValuEngine downgraded shares of Arbutus Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, December 1st. B. Riley upped their price objective on shares of Arbutus Biopharma from $9.00 to $11.50 and gave the stock a “neutral” rating in a research report on Monday, August 13th. Finally, BidaskClub downgraded shares of Arbutus Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Arbutus Biopharma presently has a consensus rating of “Hold” and a consensus target price of $6.38.

Arbutus Biopharma stock traded down $0.18 during trading hours on Friday, reaching $4.40. 2,682 shares of the stock were exchanged, compared to its average volume of 196,412. The company has a market cap of $251.31 million, a P/E ratio of -2.47 and a beta of 1.65. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.38 and a current ratio of 11.38. Arbutus Biopharma has a 52-week low of $4.01 and a 52-week high of $12.60.

Several large investors have recently bought and sold shares of ABUS. Algert Global LLC acquired a new position in shares of Arbutus Biopharma during the 2nd quarter worth $254,000. Rhumbline Advisers purchased a new position in shares of Arbutus Biopharma during the 2nd quarter worth about $243,000. Bank of New York Mellon Corp purchased a new position in shares of Arbutus Biopharma during the 2nd quarter worth about $609,000. Schwab Charles Investment Management Inc. purchased a new position in shares of Arbutus Biopharma during the 2nd quarter worth about $482,000. Finally, BlackRock Inc. lifted its holdings in shares of Arbutus Biopharma by 246.6% during the 2nd quarter. BlackRock Inc. now owns 2,391,143 shares of the biopharmaceutical company’s stock worth $17,455,000 after acquiring an additional 1,701,237 shares during the period. 42.59% of the stock is currently owned by institutional investors and hedge funds.

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi).

Featured Story: Cost of Equity For A Business, Investors

Get a free copy of the Zacks research report on Arbutus Biopharma (ABUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply